159 related articles for article (PubMed ID: 23313212)
1. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.
Ankerst DP; Till C; Boeck A; Goodman P; Tangen CM; Feng Z; Partin AW; Chan DW; Sokoll L; Kagan J; Wei JT; Thompson IM
J Urol; 2013 Jul; 190(1):70-6. PubMed ID: 23313212
[TBL] [Abstract][Full Text] [Related]
2. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
3. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.
Hernandez DJ; Han M; Humphreys EB; Mangold LA; Taneja SS; Childs SJ; Bartsch G; Partin AW
BJU Int; 2009 Mar; 103(5):609-14. PubMed ID: 19007374
[TBL] [Abstract][Full Text] [Related]
4. Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score.
Ankerst DP; Till C; Boeck A; Goodman PJ; Tangen CM; Thompson IM
Urology; 2013 Nov; 82(5):1076-81. PubMed ID: 24055241
[TBL] [Abstract][Full Text] [Related]
5. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
Ankerst DP; Hoefler J; Bock S; Goodman PJ; Vickers A; Hernandez J; Sokoll LJ; Sanda MG; Wei JT; Leach RJ; Thompson IM
Urology; 2014 Jun; 83(6):1362-7. PubMed ID: 24862395
[TBL] [Abstract][Full Text] [Related]
6. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
Ngo TC; Turnbull BB; Lavori PW; Presti JC
J Urol; 2011 Feb; 185(2):483-7. PubMed ID: 21167519
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan.
Auffenberg GB; Merdan S; Miller DC; Singh K; Stockton BR; Ghani KR; Denton BT
Urology; 2017 Jun; 104():137-142. PubMed ID: 28237530
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
Ankerst DP; Boeck A; Freedland SJ; Jones JS; Cronin AM; Roobol MJ; Hugosson J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ; Thompson IM
World J Urol; 2014 Feb; 32(1):185-91. PubMed ID: 22527674
[TBL] [Abstract][Full Text] [Related]
10. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
Kaplan SA; Roehrborn CG; Meehan AG; Liu KS; Carides AD; Binkowitz BS; Heyden NL; Vaughan ED
Urology; 2009 May; 73(5):935-9. PubMed ID: 19328538
[TBL] [Abstract][Full Text] [Related]
11. Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
Park JY; Yoon S; Park MS; Choi H; Bae JH; Moon DG; Hong SK; Lee SE; Park C; Byun SS
PLoS One; 2017; 12(1):e0168917. PubMed ID: 28046017
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
Ankerst DP; Boeck A; Freedland SJ; Thompson IM; Cronin AM; Roobol MJ; Hugosson J; Stephen Jones J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ
World J Urol; 2012 Apr; 30(2):181-7. PubMed ID: 22210512
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer risk prediction in a urology clinic in Mexico.
Liang Y; Messer JC; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
Urol Oncol; 2013 Oct; 31(7):1085-92. PubMed ID: 22306115
[TBL] [Abstract][Full Text] [Related]
14. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.
Ankerst DP; Straubinger J; Selig K; Guerrios L; De Hoedt A; Hernandez J; Liss MA; Leach RJ; Freedland SJ; Kattan MW; Nam R; Haese A; Montorsi F; Boorjian SA; Cooperberg MR; Poyet C; Vertosick E; Vickers AJ
Eur Urol; 2018 Aug; 74(2):197-203. PubMed ID: 29778349
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.
Salami SS; Vira MA; Turkbey B; Fakhoury M; Yaskiv O; Villani R; Ben-Levi E; Rastinehad AR
Cancer; 2014 Sep; 120(18):2876-82. PubMed ID: 24917122
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer risk assessment tools in an unscreened population.
Lundon DJ; Kelly BD; Foley R; Loeb S; Fitzpatrick JM; Watson RW; Rogers E; Durkan GC; Walsh K
World J Urol; 2015 Jun; 33(6):827-32. PubMed ID: 25091862
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.].
Murray NP; Fuentealba C; Reyes E; Jacob O
Arch Esp Urol; 2017 Jun; 70(5):503-512. PubMed ID: 28613202
[TBL] [Abstract][Full Text] [Related]
18. [Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population].
Zhu XD; Zheng A; Wang ZQ; Shao Q
Zhonghua Nan Ke Xue; 2018 Feb; 24(2):142-146. PubMed ID: 30156074
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
Ankerst DP; Goros M; Tomlins SA; Patil D; Feng Z; Wei JT; Sanda MG; Gelfond J; Thompson IM; Leach RJ; Liss MA
Eur Urol Focus; 2019 Jan; 5(1):54-61. PubMed ID: 29422418
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.
Haese A; Trooskens G; Steyaert S; Hessels D; Brawer M; Vlaeminck-Guillem V; Ruffion A; Tilki D; Schalken J; Groskopf J; Van Criekinge W
J Urol; 2019 Aug; 202(2):256-263. PubMed ID: 31026217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
